Browse GCNT1

Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus membrane Single-pass type II membrane protein Note=Also detected in the trans-Golgi network.
Domain PF02485 Core-2/I-Branching enzyme
Function

Glycosyltransferase that catalyzes the transfer of an N-acetylglucosamine moiety onto mucin-type core 1 O-glycan to form the branched mucin-type core 2 O-glycan. Mucin-type core 2 O-glycans play an important role in leukocyte extravasation as they serve as scaffolds for the display of the selectin ligand sialyl Lewis X by leukocytes.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0007159 leukocyte cell-cell adhesion
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0016266 O-glycan processing
GO:0032868 response to insulin
GO:0043413 macromolecule glycosylation
GO:0043434 response to peptide hormone
GO:0045123 cellular extravasation
GO:0050900 leukocyte migration
GO:0050901 leukocyte tethering or rolling
GO:0060352 cell adhesion molecule production
GO:0060993 kidney morphogenesis
GO:0061756 leukocyte adhesion to vascular endothelial cell
GO:0070085 glycosylation
GO:0072001 renal system development
GO:1901652 response to peptide
Molecular Function GO:0003829 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity
GO:0008194 UDP-glycosyltransferase activity
GO:0008375 acetylglucosaminyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016758 transferase activity, transferring hexosyl groups
Cellular Component GO:0005795 Golgi stack
GO:0005802 trans-Golgi network
GO:0031984 organelle subcompartment
GO:0031985 Golgi cisterna
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG hsa00512 Mucin type O-Glycan biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-392499: Metabolism of proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GCNT1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between GCNT1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21712812Bladder CarcinomaInhibit immunity (NK cell function)Here, we report that upregulation of C2GnT is closely correlated with progression of bladder tumours and that C2GnT-expressing bladder tumours use a novel strategy to increase their metastatic potential. Our results showed that C2GnT-expressing bladder tumour cells are highly metastatic due to their high ability to evade NK cell immunity and revealed the molecular mechanism of the immune evasion by C2GnT expression.
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GCNT1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GCNT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.290.435
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0430.954
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4720.446
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7580.08
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4360.714
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1720.465
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5180.232
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0470.353
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0820.949
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2770.154
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5390.248
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3680.0548
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GCNT1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GCNT1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GCNT1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GCNT1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GCNT1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GCNT1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GCNT1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGCNT1
Nameglucosaminyl (N-acetyl) transferase 1, core 2
Aliases C2GNT; NAGCT2; core 2 beta1,6 N-acetylglucosaminyltransferase-I; beta-1,3-galactosyl-O-glycosyl-glycoprotein ......
Chromosomal Location9q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GCNT1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.